The present invention relates to transfected primary and secondary somatic
cells of vertebrate origin, particularly mammalian origin, transfected
with exogenous genetic material (DNA) that encodes erythropoietin or an
insulinotropin (e.g., derivatives of glucagon-like peptide 1 (GLP-1)),
methods by which primary and secondary cells are transfected to include
exogenous genetic material encoding erythropoietin or an insulinotropin,
methods of producing clonal cell strains or heterogenous cell strains that
express erythropoietin or an insulinotropin, methods of gene therapy in
which the transfected primary or secondary cells are used, and methods of
producing antibodies using the transfected primary or secondary cells. The
present invention includes primary and secondary somatic cells, such as
fibroblasts, keratinocytes, epithelial cells, endothelial cells, glial
cells, neural cells, formed elements of the blood, muscle cells, other
somatic cells that can be cultured and somatic cell precursors, which have
been transfected with exogenous DNA encoding erythropoietin or an
insulinotropin, which is stably integrated into their genomes or is
expressed in the cells episomally.
